Opiate detoxification under anesthesia: No apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure

Journal of Toxicology - Clinical Toxicology

Volumn 37, Issue 1, 1999, Pages 43-50

  Pfab, Rudolf ^a,b   Hirtl, Christian ^a   Zilker, Thomas ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; DIAMORPHINE; DIHYDROCODEINE; LIOTHYRONINE; MIDAZOLAM; NALOXONE; NALTREXONE; OPIATE ANTAGONIST; PROPOFOL; THYROID HORMONE; THYROTROPIN; THYROXINE;

ADULT; ANESTHESIOLOGICAL TECHNIQUES; ARTICLE; CLINICAL ARTICLE; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENERAL ANESTHESIA; HUMAN; KIDNEY FAILURE; MALE; OPIATE ADDICTION; RESPIRATORY FAILURE; WITHDRAWAL SYNDROME;

ADULT; ANESTHESIA; CODEINE; FEMALE; HEROIN DEPENDENCE; HUMANS; KIDNEY FAILURE, ACUTE; MALE; METHADONE; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; RESPIRATORY INSUFFICIENCY; SUBSTANCE WITHDRAWAL SYNDROME; THYROID HORMONES;

EID: 0032977762     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.1081/CLT-100102407     Document Type: Article

References (26)

1. Brewer C. Ultra rapid antagonist precipitated opiate detoxification under general anesthesia or sedation. Addiction Biology 1997;2:291-302.
2. Brewer C. Opiate detoxification under anaesthesia. BMJ 1998;316:1983-1984.
3. Simon DL. Rapid opioid detoxification using opioid antagonists: History, theory and state of the art. J Addict Dis 1997;16:103-122.
4. Loimer N, Schmid RW, Presslich O, Lenz K. Continuous naloxone administration suppresses opiate withdrawal symptoms in human opiate addicts during detoxification treatment. J Psychiatr Res 1989;23:81-86.
5. Loimer N, Lenz K, Schmid R, Presslich O. Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates. Am J Psychiatry 1991;148:933-935.
6. Newman MK, Berris JM. Artificial hibernation therapy. Arch Phys Ther 1941;22:161-170.
7. Resnick RB, Fink M, Freedman AM. Cyclazocine treatment of opiate dependence: A progress report. Compr Psychiatry 1971;12:491-502.
8. Resnick RB, Kestenbaum RS, Washton A, Poole D. Naloxone-precipitated withdrawal: A method for rapid induction onto naltrexone. Clin Pharmacol Ther 1977;21:409-413.
9. San L, Puig M, Bulbena A, Farre M. High risk of ultrashort noninvasive opiate detoxification. Am J Psychiatry 1995;152:956.
10. Mayor S. Specialists criticise treatment for heroin addiction. BMJ 1997;314:1365.
11. Strang J, Beam J, Gossop M. Opiate detoxification under anaesthesia. BMJ 1997;315:1249-1250.
12. Legarda JJ, Gossop M. A 24 h inpatient detoxification treatment for heroin addicts: A preliminary investigation. Drug Alcohol Depend 1994;35:91-93.
13. Judson BA, Himmelberger DU, Goldstein A. The naloxone test for opiate dependence. Clin Pharmacol Ther 1980;27:492-501.
14. Kolb L, Himmelsbach CK. Clinical studies of drug addiction III. A critical review of withdrawal treatments with method of evaluating abstinence syndromes. Am J Psychiatry 1938;94:759-797.
15. Pfab R, Hirtl C, Hibler A, Felgenhauer N, Chlistalla J, Zilker Th. Der Antagonist-induzierte Narkosegestiitzte Opiat-Schnellentzug (AINOS). Münchner Med Wochenschrift 1996;138:781-786.
16. O'Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques. JAMA 1998;279: 229-234.
17. Röjdmark S, Adner N, Andersson D, Austern J, Lamminpaa K. Prolactin and thyrotropin responses to thyrotropin-releasing hormone and metoclopramide in men with chronic alcoholism. J Clin Endocrinol Metab 1984;59:595-600.
18. Brabant G, Prank K, Hoang-Vu C, Hesch RD, von zur Muhlen A. Hypothalamic regulation of pulsatile thyrotopin secretion. J Clin Endocrinol Metab 1991; 72:145-150.
19. Gonzalez JP, Brogden RN. Naltrexone. A Review of its pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988;35:192-213.
20. Brewer C, Razae H, Bailey C. Opioid withdrawal and naltrexone induction in 48-72 hours with minimal dropout, using a modification of the naltrexoneclonidine technique. Brit J Psychiatry 1988;153:340-343.
21. Van Tilborg KA, Rabelink TJ, Koomans HA. Naloxone inhibits renal hemodynamic effect of head-out immersion in humans. Kidney Int 1995;48:860-865.
22. DiBona GF, Jones SY. Role of endogenous peripheral opioid mechanisms in renal function. J Am Soc Nephrol 1994;4:1792-1797.
23. Hill SA, Quinn K, Shelly MP, Park GR. Reversible renal failure following opioid administration. Anaesthesia 1991;46:938-939.
24. Brimacombe J, Archdeacon S, Newell S, Martin J. Two cases of naloxone-induced pulmonary oedema-the possible use of phentolamine in management. Anaesth Intensive Care 1991;19:578-580.
25. Olsen KS. Naloxone administration and laryngospasm followed by pulmonary edema. Intensive Care Med 1990;16:340-341.
26. Wride SR, Smith RE, Courtney PG. A fatal case of pulmonary edema in a healthy young male following naloxone administration. Anaesth Intensive Care 1989;17:374-377.